Literature DB >> 3103692

The existence of apotyrosinase in the cytosol of Harding-Passey mouse melanoma melanocytes and characteristics of enzyme reconstitution by Cu(II).

J H Martínez, F Solano, A Arocas, J C García-Borrón, J L Iborra, J A Lozano.   

Abstract

This paper reports the effect of Cu(II) supplementation on the tyrosinase isozymes from Harding-Passey mouse melanoma. The dopa-oxidase activity of the microsomal and soluble isozymes is increased by incubation with Cu(II), whereas the activity of the unique 'in vivo' melanin-forming isozyme, bound to melanosomes, is not. Other divalent cations are ineffective in increasing the dopa-oxidase activity of tyrosinases. These results indicate the existence of a mixture of tyrosinase and apotyrosinase in the cytosol of melanocytes before reaching the melanosome. The paucity of Cu(II) in the cytosol could be one of the mechanisms of regulation contributing to avoid the formation of melanin outside the melanosome. Some kinetic characteristics of the enzymatic reconstitution of soluble and microsomal isozymes by Cu(II) are also studied, and the results suggest that the glycosylation of apotyrosinase during its maturation yields a conformational change favouring the binding of Cu(II) at the enzyme active site, by lowering the activation energy of the reconstitution reaction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3103692     DOI: 10.1016/0304-4165(87)90049-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  2 in total

1.  The action of glycosylases on dopachrome (2-carboxy-2,3-dihydroindole-5,6-quinone) tautomerase.

Authors:  P Aroca; J H Martinez-Liarte; F Solano; J C García-Borrón; J A Lozano
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

2.  Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.

Authors:  Markus M Forsberg; Risto O Juvonen; Petra Helisalmi; Jukka Leppänen; Joseph A Gogos; Maria Karayiorgou; Pekka T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-09-17       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.